Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer Letter uri icon

Overview

MeSH Major

  • Disease Models, Animal
  • Neoplasms
  • Oncogenes

abstract

  • © 2019, The Author(s), under exclusive licence to Springer Nature America, Inc. Pancreatic ductal adenocarcinoma is an aggressive cancer with limited treatment options1. Approximately 10% of cases exhibit familial predisposition, but causative genes are not known in most families2. We perform whole-genome sequence analysis in a family with multiple cases of pancreatic ductal adenocarcinoma and identify a germline truncating mutation in the member of the RAS oncogene family-like 3 (RABL3) gene. Heterozygous rabl3 mutant zebrafish show increased susceptibility to cancer formation. Transcriptomic and mass spectrometry approaches implicate RABL3 in RAS pathway regulation and identify an interaction with RAP1GDS1 (SmgGDS), a chaperone regulating prenylation of RAS GTPases3. Indeed, the truncated mutant RABL3 protein accelerates KRAS prenylation and requires RAS proteins to promote cell proliferation. Finally, evidence in patient cohorts with developmental disorders implicates germline RABL3 mutations in RASopathy syndromes. Our studies identify RABL3 mutations as a target for genetic testing in cancer families and uncover a mechanism for dysregulated RAS activity in development and cancer.

authors

publication date

  • January 2019

Research

keywords

  • Letter

Identity

Digital Object Identifier (DOI)

  • 10.1038/s41588-019-0475-y